Search results

Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

24 January 2018

This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

Result type

Technology appraisal guidance

Published

25 November 2015

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

25 January 2017

Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

Result type

Technology appraisal guidance

Published

25 November 2015

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

Result type

Technology appraisal guidance

Published

25 November 2015

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

26 October 2016